Search Results

NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced the appointment of Martin B. Leon, M.D. as Executive Chair of the U.S. early feasibility study (EFS) of the NeoChord Transcatheter NeXuS System, a transformational device for mitral chordal repair.

NeoChord, Inc., a privately-held medical technology company, is leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation with more than a decade of commercial experience in treating over 1,800 patients globally with the transapical technology.

NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced successful completion of the first-in-human procedure with the NeoChord NeXuS Transcatheter Mitral Chordal Repair technology (TMVr).

NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, announced positive 30-day results following the first successful worldwide procedure using multiple chords to a single anchor.

The Cardiovascular Research Foundation is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education.